Biogen Inc. $BIIB Shares Sold by Triglav Investments D.O.O.

Triglav Investments D.O.O. reduced its position in Biogen Inc. (NASDAQ:BIIB) by 33.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,130 shares of the biotechnology company’s stock after selling 6,000 shares during the quarter. Triglav Investments D.O.O.’s holdings in Biogen were worth $2,135,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. National Pension Service grew its position in shares of Biogen by 0.7% during the fourth quarter. National Pension Service now owns 287,238 shares of the biotechnology company’s stock worth $50,551,000 after buying an additional 2,036 shares in the last quarter. Basepoint Wealth LLC acquired a new position in shares of Biogen during the fourth quarter worth about $205,000. Rothschild Investment LLC grew its position in shares of Biogen by 12.3% during the fourth quarter. Rothschild Investment LLC now owns 513 shares of the biotechnology company’s stock worth $90,000 after buying an additional 56 shares in the last quarter. Northwestern Mutual Wealth Management Co. lifted its stake in Biogen by 11.0% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 6,584 shares of the biotechnology company’s stock worth $1,159,000 after purchasing an additional 654 shares during the last quarter. Finally, Moors & Cabot Inc. purchased a new stake in Biogen during the fourth quarter worth approximately $264,000. 87.93% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms recently weighed in on BIIB. Mizuho boosted their target price on Biogen from $207.00 to $236.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 10th. Wolfe Research set a $231.00 target price on Biogen in a research note on Monday, February 9th. Weiss Ratings upgraded Biogen from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, May 1st. JPMorgan Chase & Co. boosted their target price on Biogen from $175.00 to $185.00 and gave the stock a “neutral” rating in a research note on Thursday, April 23rd. Finally, Guggenheim boosted their target price on Biogen from $246.00 to $260.00 and gave the stock a “buy” rating in a research note on Thursday, April 30th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, thirteen have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Biogen has a consensus rating of “Moderate Buy” and an average price target of $215.81.

Biogen Trading Down 0.2%

NASDAQ:BIIB opened at $196.00 on Friday. The stock has a fifty day moving average price of $186.66 and a two-hundred day moving average price of $182.21. The stock has a market capitalization of $28.94 billion, a price-to-earnings ratio of 21.03, a PEG ratio of 1.73 and a beta of 0.19. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.41 and a current ratio of 3.06. Biogen Inc. has a 1 year low of $121.05 and a 1 year high of $205.97.

Biogen (NASDAQ:BIIB) last posted its earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share for the quarter, beating the consensus estimate of $2.95 by $0.62. The company had revenue of $2.48 billion for the quarter, compared to analyst estimates of $2.29 billion. Biogen had a return on equity of 12.83% and a net margin of 13.81%.Biogen’s revenue was up 1.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $3.02 earnings per share. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. As a group, sell-side analysts anticipate that Biogen Inc. will post 14.18 earnings per share for the current fiscal year.

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.